



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/462,909	02/14/2000	ANNIE MEINIEL	065691/0179	5643
7590	05/29/2002			
FOLEY & LARDNER WASHINGTON HARBOUR 3000 K STREET NW SUITE 500 PO BOX 25696 WASHINGTON, DC 20007-8696			EXAMINER [REDACTED]	CHERNYSHEV, OLGA N
		ART UNIT [REDACTED]	PAPER NUMBER 1646	
DATE MAILED: 05/29/2002				B

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address: ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

09/462,909

EXAMINER

CHERNYSHEV

ART UNIT	PAPER
----------	-------

1646 13

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

The reply filed March 13, 2002 is not fully responsive to the prior Office action because of the following omission(s) or matter(s): Applicant did not provide a proper election, i.e. single molecular embodiment of the peptide to be examined. The election of SEQ ID NO:1 is not proper because SEQ ID NO:1 encompasses multiple sequences, see Paper No.11, page 3. Applicant is required to elect a single molecular embodiment of peptide for examination, wherein the peptide is referenced with a sequence identifier. Again, Applicant is required to identify all claims that read on the elected species.

Applicant is requested in order to comply with sequence rules to correct the error reiterated in claims 2-15 with regard to appropriate number of Xaa's in claimed sequences, see page 3 of Paper No.11.

Applicant traversal with regard to rejoinder of claims 14-15 is found to be persuasive. Upon a proper election examination will include these claims in so far as they encompass the elected peptide.

Since the reply appears to be bona fide, applicant is given a TIME PERIOD of ONE (1) MONTH from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Examiner Olga N. Chernyshev, Art Unit 1646, whose telephone number is (703) 305-1003.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

CHRISTINE J. SAoud
PRIMARY EXAMINER